Abstract
Teprotumumab (teprotumumab-trbw; TEPEZZA™ – Horizon Therapeutics) is a monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist developed for the treatment of thyroid eye disease (Graves ophthalmopathy/orbitopathy, thyroid-associated ophthalmopathy). Based on positive results from two multinational clinical trials teprotumumab was recently approved for this indication in the US. This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
US Food & Drug Administration. FDA approves first treatment for thyroid eye disease [media release]. 21 Jan 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease.
Horizon Therapeutics. TEPEZZA (teprotumumab-trbw) for injection, for intravenous use. 2020. https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf. Accessed 2020.
Genmab. Genmab announces Rg1507 update [media release]. 4 Dec 2009. http://www.genmab.com.
Genmab. Teprotumumab restarts clinical development in new indication [media release]. 11 Jun 2013. http://www.genmab.com.
Horizon Pharma. Horizon Pharma plc announces agreement to acquire River Vision Development Corp. and teprotumumab (RV001), a biologic in late-stage development for rare eye disease [media release]. 8 May 2017. http://www.horizonpharma.com.
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–52.
Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–61.
Kahaly GJ, Douglas R, Holt RJ, et al. 48-week follow-up of a multicenter, randomized, double-masked, placebo-controlled treatment trial of teprotumumab in thyroid-associated ophthalmopathy [abstract no. Highlighted Oral 2]. Thyroid. 2018;28(Suppl 1):A1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
Additional information
Enhanced material for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.11905581.
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Markham, A. Teprotumumab: First Approval. Drugs 80, 509–512 (2020). https://doi.org/10.1007/s40265-020-01287-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-020-01287-y